[FORM 8-K CURRENT REPORTte of Report (Date of earliest event reported):October 29, 2013 BIOSTAR PHARMACEUTICALS, Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer oforporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, Peoples Republic of China 712046 86-029-33686638 N/A (Former name or formerdress, if changed since last report)]
[Schedule 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of securities to which transaction applies: ____________________________ (3) (4) Proposed maximum aggregate value of transaction: ______________________________________ (5)]
[Schedule 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of securities to which transaction applies: ____________________________ (3) (4) Proposed maximum aggregate value of transaction: ______________________________________ (5)]
[Schedule 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies:_____________________________ (2)gregate number of securities to which transaction applies: ____________________________ (3) (4) Proposed maximumgregate value of transaction: ______________________________________]
[Schedule 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies:_____________________________ (2)gregate number of securities to which transaction applies: ____________________________ (3) (4) Proposed maximumgregate value of transaction: ______________________________________]
[FORM S-8 SECURITIES ACT OF 1933 REGISTRATION STATEMENT UNDER THE Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 including zip code) (Full title of the plan) Ronghua Wang, President and Chief Executive Officer No. 588 Shiji Xi Avenue,] [Biostar Pharmaceuticals, Inc. 2012 Stock Option Compensation Plan This Biostar Pharmaceuticals, Inc. 2012 Stock Option Compensation Plan Plan 1. Definitions. (a) Board " (b) Code " (c) Committee Rule 16b-3 Exchange Act " (d) Company " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grant Agreement " (i) Maryland Securities Rules " (j) Option Optionee] [[Schiff Hardin letterhead] August 28, 2013 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China Ladies and Gentlemen: Schiff Hardin LLP EX-5.1 3 ex5-1.htm] [Consent of Independent Registered Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated August 28, 2013 of Biostar Pharmaceuticals, Inc. of our report dated April 11, 2013 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Certified Public Accountants Hong Kong August 28, 2013 EX-23.2 5 ex23-2.htm]
[FORM S-8 SECURITIES ACT OF 1933 REGISTRATION STATEMENT UNDER THE Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 including zip code) (Full title of the plan) Ronghua Wang, President and Chief Executive Officer No. 588 Shiji Xi Avenue,] [Biostar Pharmaceuticals, Inc. 2012 Stock Option Compensation Plan This Biostar Pharmaceuticals, Inc. 2012 Stock Option Compensation Plan Plan 1. Definitions. (a) Board " (b) Code " (c) Committee Rule 16b-3 Exchange Act " (d) Company " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grant Agreement " (i) Maryland Securities Rules " (j) Option Optionee] [[Schiff Hardin letterhead] August 28, 2013 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China Ladies and Gentlemen: Schiff Hardin LLP EX-5.1 3 ex5-1.htm] [Consent of Independent Registered Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated August 28, 2013 of Biostar Pharmaceuticals, Inc. of our report dated April 11, 2013 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Certified Public Accountants Hong Kong August 28, 2013 EX-23.2 5 ex23-2.htm]
[FORMS-8 SECURITIES ACT OF 1933 REGISTRATION STATEMENT UNDER THE Biostar Pharmaceuticals, Maryland (State or other jurisdiction oforporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China 712046luding zipde) (Full title of the plan) Ronghua Wang, President and Chief Executive Officer] [Biostar Pharmaceuticals, 2012 Stock Optionmpensation Plan This Biostar Pharmaceuticals, 2012 Stock Optionmpensation Plan Plan 1. Definitions. (a) Board " (b)de " (c)mmittee Rule 16b-3 Exchange Act " (d)mpany " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grantreement] [[Schiff Hardin letterhead] August 28, 2013 Biostar Pharmaceuticals, No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China Ladies and Gentlemen:hiff Hardin ex5-1.htm 3 EX-5.1] [Consent of Independent Registered Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Form S-8ted August 28, 2013 of Biostar Pharmaceuticals, of our reportted April 11, 2013 relating to thensolidated financial statements, which appears in the Annual Report on Form 10-K of Biostar] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Certified Public Accountants Hong Kong August 28, 2013 ex23-2.htm 5 EX-23.2]
[FORMS-8 SECURITIES ACT OF 1933 REGISTRATION STATEMENT UNDER THE Biostar Pharmaceuticals, Maryland (State or other jurisdiction oforporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China 712046luding zipde) (Full title of the plan) Ronghua Wang, President and Chief Executive Officer] [Biostar Pharmaceuticals, 2012 Stock Optionmpensation Plan This Biostar Pharmaceuticals, 2012 Stock Optionmpensation Plan Plan 1. Definitions. (a) Board " (b)de " (c)mmittee Rule 16b-3 Exchange Act " (d)mpany " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grantreement] [[Schiff Hardin letterhead] August 28, 2013 Biostar Pharmaceuticals, No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China Ladies and Gentlemen:hiff Hardin ex5-1.htm 3 EX-5.1] [Consent of Independent Registered Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Form S-8ted August 28, 2013 of Biostar Pharmaceuticals, of our reportted April 11, 2013 relating to thensolidated financial statements, which appears in the Annual Report on Form 10-K of Biostar] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Certified Public Accountants Hong Kong August 28, 2013 ex23-2.htm 5 EX-23.2]
[FORM 10-Q (Mark One) x June 30, 2013 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]
